Q32 Bio Inc.
QTTBAs of the close on Sep 25, 2026
Price
$8.77
Market cap
—
The cover-page share count does not match the latest report's share count
P/E (diluted TTM)
—
The fourth quarter's per-share figure could not be confirmed from the annual report
EPS (TTM)
—
The fourth quarter's per-share figure could not be confirmed from the annual report
Dividend yield
—
Dividend records do not yet cover the latest payments
Figures shown here come from public SEC filings. Dates beside each section show the available history.
How Q32 Bio Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Source: Q32 Bio Inc. — 10-K filed Mar 13, 2024
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 9 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 16, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| Carlyle Group Inc. | 2026-03-31 | 1,102,741 | $7.08M | SEC filing |
| ACORN CAPITAL ADVISORS, LLC | 2026-03-31 | 315,052 | $2.02M | SEC filing |
| MORGAN STANLEY | 2026-03-31 | 9,560 | $61.4K | SEC filing |
| GROUP ONE TRADING LLC | 2026-03-31 | 34 | $218 | SEC filing |
| Federation des caisses Desjardins du Quebec | 2026-03-31 | 70 | $446 | SEC filing |
| AdvisorNet Financial, Inc | 2026-03-31 | 2 | $13 | SEC filing |
| DANSKE BANK A/S | 2026-03-31 | 1 | $6 | SEC filing |
| CITADEL ADVISORS LLC | 2026-03-31 | 15,481 | $99.4K | SEC filing |
| Allworth Financial LP | 2026-03-31 | 98 | $630 | SEC filing |
| CWM, LLC | 2026-03-31 | 39 | $250 | SEC filing |
| Cambridge Investment Research Advisors, Inc. | 2026-03-31 | 35,025 | Not shown | SEC filing |
| TWO SIGMA INVESTMENTS, LP | 2026-03-31 | 42,346 | $272K | SEC filing |
| SBI Securities Co., Ltd. | 2026-03-31 | 104 | $668 | SEC filing |
| ADAR1 Capital Management, LLC | 2026-03-31 | 35,000 | $225K | SEC filing |
| BlackRock, Inc. | 2026-03-31 | 86,147 | $553K | SEC filing |
| Russell Investments Group, Ltd. | 2026-03-31 | 454 | $2.92K | SEC filing |
| Affinity Asset Advisors, LLC | 2026-03-31 | 27,777 | $178K | SEC filing |
| Sanofi | 2026-03-31 | 244,083 | $1.57M | SEC filing |
| Tower Research Capital LLC (TRC) | 2026-03-31 | 1,871 | $12K | SEC filing |
| Rockefeller Capital Management L.P. | 2026-03-31 | 577 | $3.7K | SEC filing |
- Each value is checked against Q32 Bio Inc.'s share prices from within about three months of its report date (insiders' Form 4 trades and the latest close).
- Value not shown for 1 row: the filed value is about 1,000 times too small for the share count at Q32 Bio Inc.'s share price.
Filer report history
Two reports per filer, as filed. No change is calculated, because the data on file cannot confirm that both reports describe the same security.
- UBS Group AG: 13,606 shares reported 2025-12-31; 270 shares reported 2026-03-31.
- OSAIC HOLDINGS, INC.: 132 shares reported 2025-12-31; 124 shares reported 2026-03-31.
- GEODE CAPITAL MANAGEMENT, LLC: 106,113 shares reported 2025-12-31; 118,152 shares reported 2026-03-31.
- EverSource Wealth Advisors, LLC: 4,640 shares reported 2025-12-31; 4,640 shares reported 2026-03-31.
- JANE STREET GROUP, LLC: 25,374 shares reported 2025-12-31; 65,599 shares reported 2026-03-31.
- Arax Advisory Partners: 1,111 shares reported 2025-12-31; 1,148 shares reported 2026-03-31.
- ACADIAN ASSET MANAGEMENT LLC: 48,373 shares reported 2025-12-31; 172,586 shares reported 2026-03-31.
- Pfizer Inc: 277,777 shares reported 2025-12-31; 101,618 shares reported 2026-03-31.
- ORBIMED ADVISORS LLC: 2,252,987 shares reported 2025-12-31; 2,252,987 shares reported 2026-03-31.
- ARCH Venture Management, LLC: 320,482 shares reported 2025-12-31; 320,482 shares reported 2026-03-31.
- FEDERATED HERMES, INC.: 2,273 shares reported 2025-12-31; 2,273 shares reported 2026-03-31.
- FMR LLC: 3,364 shares reported 2025-12-31; 3,400 shares reported 2026-03-31.
Showing the 12 most recent filer reports.
19 filers have only one report here.
Independent insiders buying near the same time
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-05-28 | ORBIMED ADVISORS LLC · Director, 10% owner | Common Stock | P — Open market or private purchase | +1,250,000 | 8.00 | SEC filing |
| 2026-05-28 | ORBIMED ADVISORS LLC · Director, 10% owner | Common Stock | P — Open market or private purchase | +625,000 | 8.00 | SEC filing |
| 2026-05-28 | Xu Diyong · Director, 10% owner | Common Stock | P — Open market or private purchase | +1,250,000 | 8.00 | SEC filing |
| 2026-05-28 | Xu Diyong · Director, 10% owner | Common Stock | P — Open market or private purchase | +625,000 | 8.00 | SEC filing |
| 2026-02-25 | Morrison Jodie Pope · CEO | Common Stock | S — Open market or private sale | −9,896 | 4.51 | SEC filing |
| 2026-02-25 | Violette Shelia M. · Chief Scientific Officer | Common Stock | S — Open market or private sale | −2,815 | 4.51 | SEC filing |
| 2026-02-25 | Kalowski Lee · CFO and President | Common Stock | S — Open market or private sale | −3,995 | 4.51 | SEC filing |
| 2025-12-02 | Kalowski Lee · CFO and President | Common Stock | S — Open market or private sale | −9,072 | 3.46 | SEC filing |
Showing 8 of 14 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-12 | Lundberg Sven Ante · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +9,810 | SEC filing |
| 2026-06-12 | LAPORTE KATHLEEN · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +9,810 | SEC filing |
| 2026-06-12 | Thistle Mary · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +9,810 | SEC filing |
| 2026-06-12 | GRAYZEL DAVID S. · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +9,810 | SEC filing |
| 2026-06-12 | Manke Isaac · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +9,810 | SEC filing |
| 2026-06-12 | TZIANABOS ARTHUR · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +9,810 | SEC filing |
| 2026-06-12 | Iwicki Mark T · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +9,810 | SEC filing |
| 2026-06-12 | Xu Diyong · Director, 10% owner | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +9,810 | SEC filing |
Showing 8 of 20 rows
Other activity
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2025-02-24 | GRAYZEL DAVID S. · Director | Stock Option (Right to Buy) | D — Disposition to the issuer | −2,569 | SEC filing |
| 2025-02-24 | Lundberg Sven Ante · Director | Stock Option (Right to Buy) | D — Disposition to the issuer | −12,767 | SEC filing |
| 2025-02-24 | LAPORTE KATHLEEN · Director | Stock Option (Right to Buy) | D — Disposition to the issuer | −5,431 | SEC filing |
| 2025-02-24 | Manke Isaac · Director | Stock Option (Right to Buy) | D — Disposition to the issuer | −12,767 | SEC filing |
| 2025-02-24 | Morrison Jodie Pope · CEO | Stock Option (Right to Buy) | D — Disposition to the issuer | −16,901 | SEC filing |
| 2025-02-24 | Lundberg Sven Ante · Director | Stock Option (Right to Buy) | D — Disposition to the issuer | −6,238 | SEC filing |
| 2025-02-24 | Violette Shelia M. · Chief Scientific Officer | Stock Option (Right to Buy) | D — Disposition to the issuer | −13,305 | SEC filing |
| 2025-02-24 | Lundberg Sven Ante · Director | Stock Option (Right to Buy) | D — Disposition to the issuer | −1,316 | SEC filing |
Showing 8 of 10 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.